Impact Biomedical ROA

Mitä Impact Biomedical tekee? Impact Biomedical Inc generates revenue through its subsidiary Global BioLife, Inc., which develops products like the Linebacker project for universal therapeutic drugs, Laetose as a sugar substitute, 3F (Functional Fragrance Formulation) for mosquito repellent, and Equivir/Nemovir antimicrobial medication. The company focuses on neurological, oncological, and immune-related disease treatments, alongside open-air defense initiatives targeting airborne diseases such as tuberculosis and influenza. DSS, Inc. owns Impact Biomedical as a wholly owned subsidiary, leveraging its intellectual property for drug discovery and biomedical advancements. The primary buyers of Impact Biomedical's products include healthcare providers and consumers interested in innovative treatments for neurological, oncological, and immune conditions. Open-air defense solutions are targeted at public health organizations seeking to curb airborne disease transmission. The Linebacker project and Equivir/Nemovir are positioned for pharmaceutical and medical markets, while 3F and Laetose cater to consumer and wellness sectors. Global BioLife, Inc. drives product development across four key areas, with Linebacker focusing on therapeutic platforms, Laetose serving as a dietary alternative, 3F targeting insect repellent needs, and Equivir/Nemovir addressing antimicrobial requirements. These products align with the company's mission to advance drug discovery and prevention in bio health and biomedical fields. Impact Biomedical on yksi Eurpooliin suosituimmista yhtiöistä.